OBJECTIVE: The prevalence and consequences of co-morbid axis-I and axis-II disorders as well as personality traits were examined in a large cohort of adult attention-deficit/hyperactivity disorder (AADHD) at a tertiary referral center. METHODS: In- and outpatients referred for diagnostic assessment of AADHD were screened. 372 affected probands were examined by means of the Structured Clinical Interview of DSM-IV axis-I/II disorders, the Revised NEO Personality Inventory (NEO-PI-R), and the Tridimensional Personality Questionnaire (TPQ). RESULTS: Lifetime co-morbidity with mood disorders was 57.3%, with anxiety disorders 27.2%, and with substance use disorders 45.0%. The histrionic personality disorder (35.2%) was the most frequent personality disorder. AADHD patients exhibited significantly altered scores on most of the NEO-PI-R and TPQ personality dimensions. The extent of substance abuse and dependence, as well as the presence of antisocial personality disorder alone or the cumulative number of other specific personality disorders was associated with lower psychosocial status (p<.0001). DISCUSSION: In a cohort of patients with AADHD referred to a single tertiary center co-morbidity with axis-I/II disorders was remarkably prevalent. In AADHD co-morbid mood, anxiety, and personality disorders as well as substance abuse/dependence is likely to be predictive of poor outcome.
OBJECTIVE: The prevalence and consequences of co-morbid axis-I and axis-II disorders as well as personality traits were examined in a large cohort of adult attention-deficit/hyperactivity disorder (AADHD) at a tertiary referral center. METHODS: In- and outpatients referred for diagnostic assessment of AADHD were screened. 372 affected probands were examined by means of the Structured Clinical Interview of DSM-IV axis-I/II disorders, the Revised NEO Personality Inventory (NEO-PI-R), and the Tridimensional Personality Questionnaire (TPQ). RESULTS: Lifetime co-morbidity with mood disorders was 57.3%, with anxiety disorders 27.2%, and with substance use disorders 45.0%. The histrionic personality disorder (35.2%) was the most frequent personality disorder. AADHD patients exhibited significantly altered scores on most of the NEO-PI-R and TPQ personality dimensions. The extent of substance abuse and dependence, as well as the presence of antisocial personality disorder alone or the cumulative number of other specific personality disorders was associated with lower psychosocial status (p<.0001). DISCUSSION: In a cohort of patients with AADHD referred to a single tertiary center co-morbidity with axis-I/II disorders was remarkably prevalent. In AADHD co-morbid mood, anxiety, and personality disorders as well as substance abuse/dependence is likely to be predictive of poor outcome.
Authors: James J McGough; Susan L Smalley; James T McCracken; May Yang; Melissa Del'Homme; Deborah E Lynn; Sandra Loo Journal: Am J Psychiatry Date: 2005-09 Impact factor: 18.112
Authors: Joseph Biederman; Anne Kwon; Megan Aleardi; Virginie-Anne Chouinard; Teresa Marino; Heather Cole; Eric Mick; Stephen V Faraone Journal: Am J Psychiatry Date: 2005-06 Impact factor: 18.112
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Michael Rösler; Wolfgang Retz; Petra Retz-Junginger; Georges Hengesch; Marc Schneider; Tilman Supprian; Petra Schwitzgebel; Katrin Pinhard; Nadine Dovi-Akue; Paul Wender; Johannes Thome Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-11-12 Impact factor: 5.270
Authors: Andreas Reif; T Trang Nguyen; Lena Weissflog; Christian P Jacob; Marcel Romanos; Tobias J Renner; Henriette N Buttenschon; Sarah Kittel-Schneider; Alexandra Gessner; Heike Weber; Maria Neuner; Silke Gross-Lesch; Karin Zamzow; Susanne Kreiker; Susanne Walitza; Jobst Meyer; Christine M Freitag; Rosa Bosch; Miquel Casas; Nuria Gómez; Marta Ribasès; Mónica Bayès; Jan K Buitelaar; Lambertus A L M Kiemeney; J J Sandra Kooij; Cees C Kan; Martine Hoogman; Stefan Johansson; Kaya K Jacobsen; Per M Knappskog; Ole B Fasmer; Phil Asherson; Andreas Warnke; Hans-Jörgen Grabe; Jessie Mahler; Alexander Teumer; Henry Völzke; Ole N Mors; Helmut Schäfer; Josep Antoni Ramos-Quiroga; Bru Cormand; Jan Haavik; Barbara Franke; Klaus-Peter Lesch Journal: Neuropsychopharmacology Date: 2011-07-13 Impact factor: 7.853
Authors: Andreas J Fallgatter; Ann-Christine Ehlis; Thomas Dresler; Andreas Reif; Christian P Jacob; Mauricio Arcos-Burgos; Maximilian Muenke; Klaus-Peter Lesch Journal: Eur Neuropsychopharmacol Date: 2012-12-12 Impact factor: 4.600
Authors: C Hess; A Reif; A Strobel; A Boreatti-Hümmer; M Heine; K-P Lesch; C P Jacob Journal: J Neural Transm (Vienna) Date: 2008-11-04 Impact factor: 3.575
Authors: Amanda Elton; Shanti P Tripathi; Tanja Mletzko; Jonathan Young; Josh M Cisler; G Andrew James; Clinton D Kilts Journal: Hum Brain Mapp Date: 2013-04-24 Impact factor: 5.038
Authors: Christine M Freitag; Thomas Lempp; T Trang Nguyen; Christian P Jacob; Lena Weissflog; Marcel Romanos; Tobias J Renner; Susanne Walitza; Andreas Warnke; Dan Rujescu; Klaus-Peter Lesch; Andreas Reif Journal: J Neural Transm (Vienna) Date: 2016-04-30 Impact factor: 3.575